Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease through a multicenter, randomized, double-blind, placebo-controlled Phase 3 maintenance study. The study includes a 40-week pivotal maintenance sub-study followed by a 240-week open-label extension sub-study, with a total duration of up to 286 weeks. Participants must have previously responded to treatment and completed endoscopy in a prior study phase. Participants receive subcutaneous injections of duvakitug or placebo according to the study protocol during the maintenance period. Those who complete the maintenance sub-study may continue in the open-label extension sub-study for longer-term treatment and monitoring. The treatment duration can be up to 280 weeks, including both study periods, with a total of up to 43 on-site visits planned. Throughout the trial, participants attend regular visits for assessments including clinical remission measured by the Crohns Disease Activity Index CDAI, endoscopic response, and patient-reported outcomes. Safety is monitored by tracking adverse events and antidrug antibody development. After treatment, participants have a 45-day follow-up visit. The study evaluates outcomes at Week 40 and continues monitoring throughout the extension period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of duvakitug in people with moderately to severely active Ulcerative Colitis UC. This Phase 3, multicenter, randomized, double-blind, placebo-controlled maintenance study aims to understand how well duvakitug works to maintain clinical remission and improve symptoms in participants with UC. The trial is sponsored by Sanofi and includes a large, diverse participant group aged 16 to 80 years. Participants receive subcutaneous injections of either one of three doses of duvakitug or a placebo following the study protocol. The study consists of two main periods a 40-week Pivotal Maintenance Sub-Study and a 240-week Open-Label Extension OLE Sub-Study. Those who do not join the OLE will complete a 45-day follow-up after the maintenance phase. Across both periods, participants may have up to 32 on-site visits to monitor treatment and health status. During the study, participants will undergo various assessments including endoscopy, clinical response evaluations, and symptom scoring by modified Mayo Score. Researchers will monitor clinical remission, endoscopic and histologic improvements, corticosteroid use, fatigue, abdominal pain, quality of life, and hospitalization incidence. Safety will be closely tracked through adverse event reporting and measurement of drug concentration and immune response. The total participation duration can be up to 286 weeks, allowing long-term monitoring of duvakitugs effects.
Actively Recruiting
Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.
Actively Recruiting
Researchers are evaluating the drug PALI-2108 in adults with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. This phase 2 study compares different doses of PALI-2108 against a placebo to assess how well the drug works, its safety, and how the body processes it. The study focuses on measuring clinical remission and endoscopic improvement to understand the drugs impact. Participants will receive either 15 mg or 30 mg of PALI-2108 once daily or a matching placebo. The treatment is given orally, and the study uses a randomized, double-blind design where neither participants nor researchers know which treatment is assigned. The study includes induction and maintenance therapy periods, with assessments at 12 weeks and up to 48 weeks to evaluate clinical response and remission. During the study, participants will undergo regular clinical evaluations including the modified Mayo Score assessments, endoscopic examinations, and monitoring for adverse effects. The primary outcome is the proportion of participants achieving clinical remission at Week 12. Secondary outcomes include clinical response and endoscopic improvements at Weeks 12 and 48. Participants safety and drug effects will be closely monitored throughout the study duration, which may last up to about two years from enrollment.
Actively Recruiting
Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease CD in a multinational, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. This trial includes three sub-studies designed to assess treatment effects through different induction periods and includes a follow-up for some participants. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The study duration may last up to 35 weeks, including a screening period of up to 5 weeks, a 12-week induction period in each sub-study, and a 6-week follow-up period for those not entering maintenance. Participants who continue to the pivotal maintenance study have up to 8 or 15 scheduled visits depending on their sub-study. During the study, participants undergo regular assessments including clinical remission and endoscopic response measured by Crohns Disease Activity Index CDAI, Simple Endoscopic Score for Crohns Disease SES-CD, and patient-reported outcomes. Researchers also monitor safety through adverse event tracking, serum drug levels, and antibody formation. The primary outcomes focus on remission and response at 12 weeks, with additional secondary outcomes and safety evaluations throughout the study.
Actively Recruiting
Researchers are evaluating the effects of intravenous ferric carboxymaltose FCM compared with a placebo on death risk, heart failure events, NT-proBNP levels, and quality of life in patients who recently had an acute myocardial infarction AMI and have iron deficiency. This phase 4, multicenter, randomized, double-blind, placebo-controlled clinical trial aims to assess these outcomes over a follow-up period ranging from 8 to 36 months. Participants are randomly assigned to receive either an intravenous 15-minute infusion of 1000 mg FCM diluted in saline or a placebo infusion of saline alone. The first dose is given on the day of randomization, with follow-up visits at 4, 8, 12, 18, 24, and 30 months to reassess participants and possibly repeat treatment if safety criteria are met. During the study, participants undergo evaluations including monitoring of death rates, heart failure events such as unplanned hospitalizations or emergency visits, changes in NT-proBNP concentration, and quality of life measured by the EQ-5D questionnaire. Safety and treatment effects are tracked throughout the follow-up period, which can last up to 36 months from the start of participation.